Indica Labs Advance Molecular Pathology with Multiplex RNA FISH Quantification Software


Indica Labs Advance Molecular Pathology with Multiplex RNA FISH Quantification Software

NM (I-Newswire) January 2, 2013 - Indica Labs, Inc. announced today the release of a revolutionary molecular pathology software module for automated analysis of fluorescent RNA In situ Hybridization (RNA ISH) assays. This latest software application is the first of its kind, offering whole-slide quantification of multiplexed RNA biomarkers on a cell-by-cell basis. The software rapidly generates single-cell RNA expression profiles for hundreds of thousands of cells in microscopic fluorescent images, allowing researchers to precisely measure overall expression ratios and cellular heterogeneity across entire tissue sections, tissue microarrays, and other microscope slide-based applications.

Molecular RNA assays have moved increasingly to the mainstream for major biomedical research areas including oncology and neuroscience. More recently, advancements have been made by the introduction of chromogenic RNA ISH for brightfield interpretation and multiplex RNA FISH for measuring multiple RNA biomarkers simultaneously. Until now there has been a lack of software for true cell-based quantification of these new multiplex assays. Indica has developed the Multiplex RNA FISH software for assays like RNAscope®, an award-winning multiplex single-molecule RNA ISH technology developed by Advanced Cell Diagnostics (Hayward, California). ACD CEO Yuling Luo, PhD. remarked "Multiplex quantitative analysis of gene expression in single cells while preserving cellular context is very important in today's biomedical research and molecular diagnostics. It should greatly facilitate the study of cellular heterogeneity that underlies nearly all of the biological and disease processes".

Indica's Multiplex RNA FISH module combined with their Chromogenic RNA ISH module and HALO™ platform have propelled Indica Labs' leadership with the most advanced software technologies for molecular pathology image analysis. Indica CEO, Steven Hashagen commented "With the release of this software, Indica Labs offers the most complete RNA ISH quantification suite for both brightfield and fluorescence; meanwhile we have a number of exciting related technologies in development."

For more information please visit http://indicalab.com/product-fluorescent-rna-ish.html or contact info@indicalab.com.




Additional Images

       


About Indica Labs

Indica Labs provides software for quantitative evaluation of pathology images. Indica's HALO™ im   More..age analysis platform provides a unique combination of precision, performance, scalability, and usability. Indica's broad range of industry leading tissue-specific image analysis algorithms can be used in a variety of truly integrated digital pathology environments, allowing pharmaceutical, healthcare, and research organizations worldwide to apply high-throughput image quantification in areas such as neuroscience, metabolism, oncology, toxicological pathology, and more. For more information, please visit http://indicalab.com or contact info@indicalab.comLess..

Contact Information

Indica Labs
Steven Hashagen
274 Calle Conejo
Suite B
87048
Phone : 505 573-5167

Published in:

Science and Research

Published On:

January 2, 2013

Print Release:

Print Release

Visit Indica Labs Website

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.